81 Evaluation of clarity of the STOPP/START criteria - SI Table SI1.1. Continued. STOPP Action Clarity rating Condition Clarity rating Explanation Clarity rating C3 Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors 67% with concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding 33% (high risk of bleeding).. 58% C4 Aspirin plus clopidogrel 100% as secondary stroke prevention, unless the patient has a coronary stent(s) inserted in the previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid arterial stenosis 83% (no evidence of added benefit over clopidogrel monotherapy) . 83% C5 Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 100% in patients with chronic atrial fibrillation 67% (no added benefit from aspirin). 83% C6 Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 67% in patients with stable coronary, cerebrovascular or peripheral arterial disease 33% (no added benefit from dual therapy). 67% C7 Ticlopidine 100% in any circumstances 100% (clopidogrel and prasugrel have similar efficacy, stronger evidence and fewer sideeffects).. 92% 2
RkJQdWJsaXNoZXIy MTk4NDMw